```html

Yellow Rash (Xanthoma): What It Is, Why It Occurs, and What to Do About It

What is Yellow rash (xanthoma)?

A xanthoma is a yellow‑orange, often slightly raised, skin lesion that results from the buildup of lipids (fat) within cells called macrophages. These lipid‑laden cells cluster in the dermis, giving the rash its characteristic color. Xanthomas are not infections or allergic reactions; they are a visible sign that something is affecting the body’s lipid metabolism or immune system.

While a single, small xanthoma may be harmless, multiple or large lesions frequently point to an underlying medical condition that needs evaluation. The term “yellow rash” is used colloquially, but clinicians refer to the specific type of lesion (e.g., eruptive, tuberous, tendinous, or plane xanthoma) when describing the pattern and location.

Common Causes

The appearance of xanthomas can stem from a wide range of disorders. Below are the most frequently encountered causes:

• Familial Hypercholesterolemia (FH): A genetic defect in the LDL‑receptor causing markedly high LDL‑cholesterol.
• Familial Dysbetalipoproteinemia (Type III hyperlipoproteinemia): Impaired clearance of chylomicron and VLDL remnants, often producing eruptive xanthomas.
• Primary biliary cholangitis (PBC) and other cholestatic liver diseases: Elevated bilirubin and cholesterol can lead to planar xanthomas on the hands and eyelids.
• Diabetes mellitus (especially uncontrolled): High triglycerides may cause eruptive xanthomas on the trunk and extensor surfaces.
• Hypertriglyceridemia (familial or secondary): Severe elevations (> 1000 mg/dL) are linked to eruptive or tuberous xanthomas.
• Nascent or advanced atherosclerotic disease: Tendinous xanthomas on the Achilles tendon or extensor tendons of the hands are classic for FH.
• Monoclonic gammopathies (e.g., multiple myeloma, Waldenström macroglobulinemia): May produce planar or papular xanthomas due to abnormal lipid metabolism.
• Systemic inflammatory diseases (e.g., sarcoidosis, lupus erythematosus): Inflammatory cytokines can alter lipid handling, leading to xanthoma formation.
• Medications that raise lipids (e.g., isotretinoin, protease inhibitors, cyclosporine): Drug‑induced hyperlipidemia may trigger eruptive lesions.
• Rare lipid storage disorders (e.g., Niemann‑Pick disease, Gaucher disease): Accumulation of sphingolipids produces characteristic yellow papules.

Associated Symptoms

Because xanthomas often signal an underlying metabolic abnormality, several other signs may coexist:

• Chest pain or claudication – possible coronary or peripheral artery disease.
• Palpitations or shortness of breath – may indicate cardiac involvement from atherosclerosis.
• Abdominal pain, hepatomegaly, or jaundice – suggest liver disease or cholestasis.
• Fatigue, unexplained weight loss, or night sweats – red flags for hematologic malignancies.
• Polyuria, polydipsia, blurred vision – classic features of uncontrolled diabetes.
• Family history of premature heart attacks, stroke, or high cholesterol.
• Joint pain or tendon thickness – seen with tendinous xanthomas.
• Skin dryness or scaling (especially in plane xanthomas of the palms/soles).

When to See a Doctor

Any new yellowish skin lesion that persists for more than a few weeks should be evaluated, but urgent medical attention is warranted when any of the following occur:

• Rapid increase in size or number of lesions.
• Pain, tenderness, or swelling over a tendon (possible tendinous xanthoma).
• Signs of a heart attack or stroke (chest pain, sudden weakness, speech difficulty).
• Severe abdominal pain, jaundice, or dark urine (possible liver dysfunction).
• Unexplained high fevers, night sweats, or weight loss.
• History of a genetic lipid disorder in the family with new skin changes.
• Any lesion that becomes ulcerated, infected, or starts to bleed.

Diagnosis

Evaluating a yellow rash involves a combination of visual assessment, laboratory testing, and sometimes imaging or tissue sampling.

Clinical Examination

• Describe the lesion: size, shape, distribution, texture (flat vs. papular vs. nodular).
• Identify characteristic locations: eyelids (xanthelasma), Achilles tendon, extensor surfaces, palms/soles.
• Assess for tendon thickening or joint involvement.

Laboratory Tests

• Lipid panel: Total cholesterol, LDL‑C, HDL‑C, triglycerides.
• Liver function tests (LFTs): ALT, AST, alkaline phosphatase, bilirubin.
• Blood glucose & HbA1c: Screen for diabetes.
• Serum protein electrophoresis (SPEP) & immunofixation: Detect monoclonal gammopathies.
• Thyroid function tests: Hypothyroidism can alter lipid metabolism.

Imaging & Specialized Studies

• Ultrasound or MRI of tendons: Measure thickness (e.g., Achilles tendon > 9 mm suggests FH).
• Coronary artery calcium scoring or carotid ultrasound: Evaluate atherosclerotic burden.

Skin Biopsy

In atypical cases, a 4‑mm punch biopsy stained with Oil‑Red‑O or Sudan III will demonstrate lipid‑laden macrophages, confirming the diagnosis.

Treatment Options

Treatment focuses on two pillars: addressing the underlying cause and managing the skin lesions themselves.

1. Treat the Underlying Metabolic Disorder

• Statins (e.g., atorvastatin, rosuvastatin): First‑line for high LDL‑C; reduce cardiovascular risk and can shrink tendinous xanthomas over months.
• Fibrates (gemfibrozil, fenofibrate): Particularly effective for severe hypertriglyceridemia and eruptive xanthomas.
• PCSK9 inhibitors (evolocumab, alirocumab): Powerful LDL‑C reducers for familial hypercholesterolemia when statins are insufficient.
• Ezetimibe: Lowers intestinal cholesterol absorption; useful as add‑on therapy.
• Niacin: Can lower triglycerides and raise HDL‑C, but side‑effects limit use.
• Management of diabetes: Lifestyle changes, metformin, GLP‑1 agonists or SGLT2 inhibitors; tighter glucose control often leads to regression of eruptive xanthomas.
• Treatment of liver disease: Ursodeoxycholic acid for PBC, lifestyle modifications for non‑alcoholic fatty liver disease.
• Oncologic therapy: For monoclonal gammopathies, appropriate chemotherapy or immunotherapy may resolve associated xanthomas.

2. Direct Dermatologic Management

• Topical treatments: Limited benefit, but high‑potency corticosteroid creams can reduce inflammation if lesions are irritated.
• Laser therapy (e.g., CO₂ or Er:YAG): Can selectively ablate superficial xanthomas, especially on the face or eyelids.
• Cryotherapy: Occasionally used for small, isolated lesions.
• Surgical excision: Reserved for large, symptomatic nodular xanthomas or when cosmetic concern is high.
• Regular monitoring: Many xanthomas shrink spontaneously once lipid levels are controlled; routine follow‑up every 3–6 months is typical.

3. Lifestyle & Home Measures

• Adopt a heart‑healthy diet: high in fiber, low in saturated/trans fats, and limited refined carbohydrates.
• Exercise ≥150 minutes of moderate‑intensity aerobic activity weekly.
• Quit smoking and limit alcohol, as both exacerbate dyslipidemia.
• Maintain a healthy weight; even modest weight loss (5–10 % of body weight) can lower triglycerides.
• Stay hydrated and limit sugary beverages, which raise triglycerides.

Prevention Tips

While you cannot prevent genetic lipid disorders, you can mitigate the risk of secondary xanthomas by adopting healthy habits and monitoring at‑risk individuals.

• Know your family history: If close relatives have early heart disease or high cholesterol, ask your clinician for lipid screening starting in childhood.
• Regular lipid checks: Adults should have a fasting lipid panel at least every 5 years; more often if you have risk factors.
• Control blood sugar: Screen for diabetes at age 45 or earlier if overweight.
• Limit medications that raise lipids: Discuss alternatives with your provider if you need isotretinoin or certain antiretrovirals.
• Monitor liver health: Abnormal liver enzymes warrant further evaluation for cholestasis, which can precipitate xanthomas.
• Stay active and maintain a balanced diet: The cornerstone of primary prevention for most lipid‑related conditions.

Emergency Warning Signs

---

© 2026 HealthConnect. Content reviewed by board‑certified dermatologists and lipid specialists. Sources: Mayo Clinic, Cleveland Clinic, National Institutes of Health (NIH), American Heart Association, CDC, WHO, and peer‑reviewed journals (J Am Coll Cardiol, Lipids in Health and Disease).

```